158 related articles for article (PubMed ID: 31523652)
1. In Vitro Activity of Amphotericin B in Combination with Statins against Clinical and Environmental
Naeimi Eshkaleti M; Kordbacheh P; Hashemi SJ; Falahati M; Zaini F; Mirhendi H; Safara M; Hosseinpoor L
Iran J Public Health; 2019 May; 48(5):943-948. PubMed ID: 31523652
[TBL] [Abstract][Full Text] [Related]
2. Statin Concentrations Below the Minimum Inhibitory Concentration Attenuate the Virulence of Rhizopus oryzae.
Bellanger AP; Tatara AM; Shirazi F; Gebremariam T; Albert ND; Lewis RE; Ibrahim AS; Kontoyiannis DP
J Infect Dis; 2016 Jul; 214(1):114-21. PubMed ID: 26984141
[TBL] [Abstract][Full Text] [Related]
3. Comparative pharmacodynamics of amphotericin B lipid complex and liposomal amphotericin B in a murine model of pulmonary mucormycosis.
Lewis RE; Albert ND; Liao G; Hou J; Prince RA; Kontoyiannis DP
Antimicrob Agents Chemother; 2010 Mar; 54(3):1298-304. PubMed ID: 20038620
[TBL] [Abstract][Full Text] [Related]
4. In vitro antifungal susceptibility of clinical species belonging to Aspergillus genus and Rhizopus oryzae.
Kachuei R; Khodavaisy S; Rezaie S; Sharifynia S
J Mycol Med; 2016 Mar; 26(1):17-21. PubMed ID: 26852191
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of aerosolized liposomal amphotericin B against murine invasive pulmonary mucormycosis.
Mihara T; Kakeya H; Izumikawa K; Obata Y; Nishino T; Takazono T; Kosai K; Morinaga Y; Kurihara S; Nakamura S; Imamura Y; Miyazaki T; Tsukamoto M; Yamamoto Y; Yanagihara K; Tashiro T; Kohno S
J Infect Chemother; 2014 Feb; 20(2):104-8. PubMed ID: 24462443
[TBL] [Abstract][Full Text] [Related]
6. Comparative study of the efficacy of liposomal amphotericin B and amphotericin B deoxycholate against six species of Zygomycetes in a murine lethal infection model.
Takemoto K; Yamamoto Y; Kanazawa K
J Infect Chemother; 2010 Dec; 16(6):388-95. PubMed ID: 20535522
[TBL] [Abstract][Full Text] [Related]
7. Comparative in vitro activities of posaconazole, voriconazole, itraconazole, and amphotericin B against Aspergillus and Rhizopus, and synergy testing for Rhizopus.
Arikan S; Sancak B; Alp S; Hascelik G; McNicholas P
Med Mycol; 2008 Sep; 46(6):567-73. PubMed ID: 19180726
[TBL] [Abstract][Full Text] [Related]
8. Frequency of occurrence, seasonal variation and antifungal susceptibility of opportunistic Mucorales isolated from hospital soils in Iran.
Vaezi A; Walther G; Kurzai O; Mahdi D; Dadashzadeh M; Nasri E; Diba K; Badali H; Fakhim H
Mycoses; 2021 Jul; 64(7):780-787. PubMed ID: 33835599
[TBL] [Abstract][Full Text] [Related]
9. Voriconazole pre-exposure selects for breakthrough mucormycosis in a mixed model of Aspergillus fumigatus-Rhizopus oryzae pulmonary infection.
Lewis RE; Liao G; Wang W; Prince RA; Kontoyiannis DP
Virulence; 2011; 2(4):348-55. PubMed ID: 21788730
[TBL] [Abstract][Full Text] [Related]
10. Antifungal activity of colistin against mucorales species in vitro and in a murine model of Rhizopus oryzae pulmonary infection.
Ben-Ami R; Lewis RE; Tarrand J; Leventakos K; Kontoyiannis DP
Antimicrob Agents Chemother; 2010 Jan; 54(1):484-90. PubMed ID: 19858263
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro antifungal susceptibility activity of amphotericin B versus amphotericin B methyl ester against Candida albicans ocular isolates.
Thanathanee O; Miller D; Ringel DM; Schaffner CP; Alfonso EC; O'Brien TP
J Ocul Pharmacol Ther; 2012 Dec; 28(6):589-92. PubMed ID: 22788845
[TBL] [Abstract][Full Text] [Related]
12. A prospective study of mucormycosis in north India: experience from a tertiary care hospital.
Bala K; Chander J; Handa U; Punia RS; Attri AK
Med Mycol; 2015 Apr; 53(3):248-57. PubMed ID: 25587084
[TBL] [Abstract][Full Text] [Related]
13. Combination treatment of liposomal amphotericin B and isavuconazole is synergistic in treating experimental mucormycosis.
Gebremariam T; Gu Y; Singh S; Kitt TM; Ibrahim AS
J Antimicrob Chemother; 2021 Sep; 76(10):2636-2639. PubMed ID: 34263306
[TBL] [Abstract][Full Text] [Related]
14. Targeted Delivery of Antifungal Liposomes to
Choudhury QJ; Ambati S; Lewis ZA; Meagher RB
J Fungi (Basel); 2022 Mar; 8(4):. PubMed ID: 35448583
[TBL] [Abstract][Full Text] [Related]
15. Improved In Vitro Anti-
Brunet K; Diop CAB; Chauzy A; Prébonnaud N; Marchand S; Rammaert B; Tewes F
J Fungi (Basel); 2022 Jan; 8(2):. PubMed ID: 35205875
[TBL] [Abstract][Full Text] [Related]
16. In vitro antifungal activity of MMV Pathogen Box® compounds alone or in combination with antifungal drugs against mucormycosis agents.
Almeida-Silva F; Tenório-Alvarenga PH; da Costa RV; Coelho RA; de Sousa Araújo GR; Zancopé-Oliveira RM; Frases S; Almeida-Paes R
Curr Res Microb Sci; 2024; 6():100242. PubMed ID: 38799088
[TBL] [Abstract][Full Text] [Related]
17. Mucormycosis in Iran: A six-year retrospective experience.
Dolatabadi S; Ahmadi B; Rezaei-Matehkolaei A; Zarrinfar H; Skiada A; Mirhendi H; Nashibi R; Niknejad F; Nazeri M; Rafiei A; Gharaghani M; Erami M; Taghipour S; Piri F; Makimura K
J Mycol Med; 2018 Jun; 28(2):269-273. PubMed ID: 29545123
[TBL] [Abstract][Full Text] [Related]
18. Monotherapy or combination therapy of isavuconazole and micafungin for treating murine mucormycosis.
Gebremariam T; Wiederhold NP; Alqarihi A; Uppuluri P; Azie N; Edwards JE; Ibrahim AS
J Antimicrob Chemother; 2017 Feb; 72(2):462-466. PubMed ID: 27798213
[TBL] [Abstract][Full Text] [Related]
19. Tacrolimus enhances the potency of posaconazole against Rhizopus oryzae in vitro and in an experimental model of mucormycosis.
Lewis RE; Ben-Ami R; Best L; Albert N; Walsh TJ; Kontoyiannis DP
J Infect Dis; 2013 Mar; 207(5):834-41. PubMed ID: 23242544
[TBL] [Abstract][Full Text] [Related]
20. Virulence Attributes and Antifungal Susceptibility Profile of Opportunistic Fungi Isolated from Ophthalmic Infections.
Sav H; Ozdemir HG; Altınbas R; Kiraz N; Ilkit M; Seyedmousavi S
Mycopathologia; 2016 Oct; 181(9-10):653-61. PubMed ID: 27193295
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
